ÅIÅsa Ingvar

Åsa Ingvar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Åsa Ingvar has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Indoor Tanning in Europe: Temporal Trends, Sociodemographic Determinants from the Euromelanoma Campaign (2009–2018)

    by Aurora Gaeta, Mariano Suppa, Hassane Njimi, Nikolay Nikolaevich Potekaev, Alexander J. Stratigos, Alexander Katoulis, Åsa Ingvar, Ada Girnita, Olga Bogomolets, Jean-Luc Bulliard, et al.

    Background: In 2009, the International Agency for Research on Cancer (IARC) classified UV-emitting tanning devices as carcinogenic to humans (Group 1). This study aimed to describe ten-year trends in sunbed use prevalence across Europe and examine differences by country and sociodemographic and phenotypic characteristics. Methods: Euromelanoma survey data collected between 2009 and 2018 from 33 countries were analysed among individuals voluntarily attending free skin examinations. Annual sunbed use prevalence and 95% confidence intervals were estimated by country, with stratified analyses by gender, age, education level, and skin phototype. Associations with sunbed use were investigated using mixed-effects logistic regression models. Results: A total of 343,675 participants were included. Among Euromelanoma campaign participants, current sunbed use declined over the study period, declining from approximately 12.8% in 2009 to below 6% by 2018, despite year-to-year fluctuations. Women, adults aged 20–35 years and individuals with skin phototypes III–IV exhibited the highest odds of sunbed use (OR Female vs. Male = 3.01, 95%CI [2.91–3.12], OR 20–35 vs. >35 = 2.54, 95%CI [2.47–2.61], and OR Type III–IV vs. Type I–II = 1.52, 95%CI [1.47–1.56], respectively). Marked heterogeneity was observed across countries. Mixed-effects analyses showed a strong temporal decline that was significantly steeper among younger participants, particularly those aged 20–35 years, than among individuals older than 35 years. Conclusions: Indoor tanning prevalence declined across Europe between 2009 and 2018, during a period of evolving post-IARC regulatory and preventive measures. Persistent sociodemographic disparities and substantial between-country heterogeneity highlight the need for targeted, country-specific prevention strategies and continued monitoring of indoor tanning behaviors.

  • Open Access

    Representational Design for Clinical AI: Embedding Secondary Stakeholder Needs in Large Language Models

    by Hubert D. Zając, Katrine Bear, Cille Wehlast Nielsen, Anette Bygum, Åsa Ingvar, Jakob T. Madsen, Kari Nielsen, Elizabeth V. Seiverling, Robert R. Stavert, Tine Vestergaard, et al.

  • Open Access

    European Expert Consensus on Essential Variables for Teledermatological Assessment of Skin Tumours

    by Alexander Detlefsen, Tine Vestergaard, Niels Kvorning Ternov, Lars Konge, Åsa Ingvar, Kari Nielsen, Kasper Bostlund Assersen

    Teledermatology is increasingly used for the assessment of suspicious skin tumours, yet referral content remains poorly standardiszed. To develop a European expert consensus on the essential clinical and visual variables required for teledermatological assessment of primary skin tumours. A three3-round modified Delphi study was conducted among experienced dermatologists. In round 1, participants proposed essential variables. In round 2, variables were rated for essentiality, clinical relevance, and feasibility. In round 3, binary voting was used to define final consensus. Consensus was predefined as ≥67 %% agreement. Interquatile ranges were calculated to assess response stability. A total of 47 variables were proposed in round 1. Following quantitative scoring, 34 variables progressed to round 3. Twelve variables met the predefined consensus threshold, primarily related to image quality and lesion characteristics. Sensitivity analyses using geographic subgroups and higher consensus thresholds demonstrated that image-quality variables were the most robust. This European expert consensus defines a focused and clinically practical core dataset for teledermatological assessment of skin tumours. These variables may support standardiszation of referrals and facilitate future validation and AI-assisted workflows.


  • Open Access

    Evaluating COVID-19 Pandemic Impact on Melanoma Incidence and factors in Regions with Different Infection Control Strategies

    by Cecilia Sand, Dilki Jayasinghe, Rory Wolfe, Victoria Mar, Karolin Isaksson, Åsa Ingvar

    Introduction: The COVID-19 pandemic significantly disrupted melanoma care worldwide, raising concerns about diagnosis and treatment delays. Objectives: To compare changes in incidence and prognostic factors of invasive cutaneous melanomas across two regions with contrasting COVID-19 infection control strategies. Methods: A retrospective population-based registry study using the Swedish quality registry for cutaneous melanoma (SweMR) and the Cancer Council in Victoria, Australia was performed. Incident invasive melanomas diagnosed between 2013 and 2021 were used for trend analyses considering the long-term underlying trends and seasonality. Regression models were used for analyses of prognostic variables (Breslow thickness, ulceration, lymph node status), comparing the time periods, “before COVID” and “during COVID” (using 1 March 2020 as interruption point). Results: In Victoria, melanoma diagnoses declined during COVID across all age groups, most notably among patients <50 years. Median Breslow thickness remained 0.7mm, but the distribution shifted significantly (p<0.001), with an 8% increase in geometric mean ratio (95% CI, 5%–12%). In Sweden, measures of thickness remained unchanged during COVID, but the odds of ulceration increased slightly (OR 1.09; 95% CI 1.01–1.19). Lymph node metastasis rates were stable in both regions. A significant immediate drop in overall incidence followed COVID-19 onset in both regions, primarily driven by thin melanomas. In Victoria, the lower incidence level persisted without a subsequent slope change. In contrast, the Swedish melanoma incidence gradually realigned with the pre-COVID trend after the initial level change. The immediate incidence drop was most prominent among older age groups in both regions. Conclusions: COVID-19 influenced melanoma incidence and prognostic features in both Sweden and Victoria. Reduced incidence of particularly thin melanomas and modest worsening of prognostic markers were observed. Victoria showed a more sustained impact, possibly reflecting the stricter and longer-lasting pandemic control measures.

  • Open Access

    Image enhancements by CLAHE and gamma correction do not improve diagnostic accuracy in teledermoscopy: a retrospective cohort study

    by Hedvig Kristensson, Carolina Nätterdahl, Bertil Persson, Karim Saleh, Johan Kappelin, Teo Helkkula, Fredrik Johansson, Johan Palmgren, Jan Lapins, Niki Rados, et al.

    Teledermoscopy (TDS) offers an efficient alternative to face-to-face assessment of suspicious skin lesions. Although diagnostic accuracy in TDS is relatively high, further improvement is desirable to reduce the risk of overlooked skin cancers and unnecessary interventions of benign lesions. Image enhancement (IE), i.e. digital modification of different parameters of an image, may potentially improve visualisation and thereby diagnostic accuracy. Several tools for IE were reviewed through two workshops and two were eventually selected for the study: Contrast Limited Adaptive Histogram Equalisation (CLAHE) for contrast enhancement and Gamma Correction for brightness adjustment. A retrospective randomized clinical study was performed in which 1997 TDS cases were distributed to 13 assessors with varying dermoscopic experience, who assessed lesions either with access to IE-tools (IE-group) or without (control group). Diagnostic accuracy for malignant vs. benign and melanoma-group vs. non-melanoma-group lesions was compared using chi-square tests. A generalized linear mixed model (GLMM) with assessor as a random intercept and adjustment for image quality was applied to account for assessor-dependent variance. Management recommendations were analyzed using both graded intervention levels relative to a gold standard and a stricter harm–benefit framework, assessing inappropriately under-management of malignant and over-management of benign lesions. No significant differences were found between the groups regarding malignant/benign classification. For melanoma differentiation, specificity was slightly, but significantly lower in the IE group compared to the control group (86.3; 95% confidence interval (CI) 83.8–88.5 vs. 89.9%; 95% CI 87.6–91.8, respectively, p = 0.02) while sensitivity remained unchanged. GLMM analyses confirmed these findings. No significant differences were observed in appropriateness of management recommendations or diagnostic confidence. Use of the IE tools CLAHE and Gamma Correction did not improve diagnostic performance in TDS assessments. These findings do not support routine clinical use of these IE tools for the purpose of improving diagnostic assessment of skin lesions.

  • Open Access

    Antihypertensive Medication as a Risk Factor For Basal Cell Carcinoma: A Nationwide Registry-based Case-control Study

    by Johan Kappelin, Ingela Ahnlide, Gustav B. Christensen, Åsa Ingvar, Kari Nielsen

    Hydrochlorothiazide has been associated with increased cutaneous squamous cell carcinoma risk. Meanwhile, its association with basal cell carcinoma (BCC) risk is controversial. The association between commonly prescribed antihypertensive medications and BCC risk in the Swedish population was investigated. All cases with a histopathologically verified BCC in Sweden during 2007–2017 and 2 matched controls per case were included in this nationwide, registry-based, case-control study. Information on prescribed anti-hypertensive drugs, comorbidities, co-medications, and socioeconomic factors was retrieved from nationwide registries. The odds of being treated with any of the chosen treatments in relation to BCC diagnosis were estimated. In total, 133,539 cases and 257,849 controls were studied. Thiazide-containing combination treatments (OR 1.09), angiotensin II receptor blockers (OR 1.09), calcium channel blockers (OR 1.09), and beta-blockers (OR 1.07) were associated with an increased BCC risk. Use of single-agent thiazide treat-ment did not affect BCC risk. In conclusion, statistically significant associations were found between several commonly prescribed antihypertensives and an increased BCC risk. Thiazide treatment affected BCC risk only when given as combination treatment, indicating that relevant adjunctive substances should be studied further in relation to BCC risk. Presently, it is suggested that prevention efforts focus on UV protection rather than altering antihypertensive treatments.


  • Fine-Grained Classification of Unpigmented Skin Cancer from Paired Dermatoscopy Images

    by Anna Gummeson, Gabrielle Flood, Kari Nielsen, Carolina Nätterdahl, Fredrik Johansson, Åsa Ingvar, Ida Arvidsson

  • Teledermoscopic triage of melanoma-suspicious skin lesions is safe: A retrospective comparative diagnostic accuracy study with multiple assessors

    by Gustav Gede Nervil, Niels Kvorning Ternov, Henrik Lorentzen, Charles Kromann, Åsa Ingvar, Kari Nielsen, Martin Tolsgaard, Tine Vestergaard, Lisbet Rosenkrantz Hölmich

    Background: The rising incidence of melanoma and the high number of benign lesions excised due to diagnostic uncertainty highlight the need for effective patient triage. This study assesses the safety and accuracy of teledermoscopic triage on a high-prevalence case set with pre-triaged, challenging, melanoma-suspicious lesions. Methods: Five dermatologists independently reviewed 250 retrospectively extracted patient cases. Teledermoscopy assessments were simulated for panels of 1, 2, 3 and 5 assessors using two distinct consensus strategies, Caution Protocol and Majority Vote, and the sensitivity and specificity of the patient triages were calculated. Results: Triage by a single teledermatologist showed a sensitivity of 92.3% and a specificity of 58.7%. Sensitivity improved with the number of assessors, particularly when using the Caution Protocol, though with a considerable drop in specificity. The Majority Vote showed a more balanced improvement in sensitivity and specificity. Safety analyses indicated that diagnostic accuracy decreased with poor image quality and increased case difficulty. Discussion: Expert teledermoscopic triage of melanocytic skin lesions is highly sensitive and lowers the need for unnecessary excision procedures by half while dismissing as few as 0.4% (95% confidence interval 0–0.6%) of melanomas, even when applied to a high-prevalence pre-triaged subpopulation. Implementation of safety procedures increases accuracy. Using multiple teledermatologists increases sensitivity but at the cost of specificity unless a Majority Vote consensus strategy is applied. Future teledermoscopy guidelines should encompass safety procedures and protocols for disagreement between assessors.


  • Open Access

    The Burden of Multiple Basal Cell Carcinomas: A Population-wide Study

    by Johan Kappelin, Ingela Ahnlide, Åsa Ingvar, Kari Nielsen

    Basal cell carcinoma (BCC) is a common skin cancer type and affected individuals are known to be at risk of developing multiple consecutive tumours. Research into BCC multiplicity has, thus far, been challenging, due to a lack of national registration. This registry-based cohort study aimed to analyse the occurrence of multiple BCCs in Sweden, and risk factors for subsequent primary BCCs. Data regarding all histopathologically verified, primary BCC tumours in Sweden from 2004 to 2017 was extracted from the Swedish BCC Registry. Risk of developing a subsequent BCC in relation to person-related factors was estimated with Cox regression analysis. Cumulative risk of BCC development after 1 or 3 earlier BCCs was estimated. In total, 39.9% of individuals with a registered BCC had at least 2 registered tumours. The risk of developing a subsequent BCC increased significantly in males, older age, and with residence in southern Sweden. The cumulative 5-year risk of developing an additional BCC after first diagnosis was approximately 30% in males and 27% in females and increased after multiple previous BCCs. This study showed the cumulative risk of a subsequent BCC to increase with a history of multiple BCCs, indicating the need for clinical surveillance in these individuals.


  • Open Access

    Examining labelling guidelines for AI‐based software as a medical device: A review and analysis of dermatology mobile applications in Australia

    by Ayooluwatomiwa Oloruntoba, Åsa Ingvar, Maithili Sashindranath, Ojochonu Anthony, Lisa Abbott, Pascale Guitera, Tony Caccetta, Monika Janda, H. Peter Soyer, Victoria Mar

    In recent years, there has been a surge in the development of AI‐based Software as a Medical Device (SaMD), particularly in visual specialties such as dermatology. In Australia, the Therapeutic Goods Administration (TGA) regulates AI‐based SaMD to ensure its safe use. Proper labelling of these devices is crucial to ensure that healthcare professionals and the general public understand how to use them and interpret results accurately. However, guidelines for labelling AI‐based SaMD in dermatology are lacking, which may result in products failing to provide essential information about algorithm development and performance metrics. This review examines existing labelling guidelines for AI‐based SaMD across visual medical specialties, with a specific focus on dermatology. Common recommendations for labelling are identified and applied to currently available dermatology AI‐based SaMD mobile applications to determine usage of these labels. Of the 21 AI‐based SaMD mobile applications identified, none fully comply with common labelling recommendations. Results highlight the need for standardized labelling guidelines. Ensuring transparency and accessibility of information is essential for the safe integration of AI into health care and preventing potential risks associated with inaccurate clinical decisions.